Dronabinol Opioid Sparing Evaluation (DOSE) Trial

Dose-Titration Study to Evaluate the Opioid-Sparing Effect of Dronabinol When Coadministered With Opioid Analgesics to Chronic Pain Patients

This study will be a 12-week, open-label trial that is designed to evaluate the Opioid-Sparing effect of Dronabinol at ranging doses when coadministered with the opioid analgesics that are currently being prescribed to patients for their chronic pain condition. The purpose of this trial will be to assess the effectiveness of Dronabinol when combined with opioid analgesics to relieve pain at lower opioid doses and to evaluate any reduction of opioid-related side effects. Participants will take the study-drug, Dronabinol, along with their regular prescribed opioids and the results will be evaluated and analyzed according to defined endpoints.

Study Overview

• Status: Unknown
• Conditions: Chronic Pain
• Intervention / Treatment: Drug: Dronabinol

Detailed Description

Week one of the study is a Baseline Period during which time, baseline data related to opioid dose and frequency, mood, sleep, bowel movements, and pain intensity will be collected. Participants will receive no Dronabinol during week one and will continue to take their stabilized dose of regular prescribed opioids, both baseline and rescue.

Weeks two through four is the Titration Period, during which time study participants will titrate the Dronabinol dose up to a daily dose of 20 mg of Dronabinol per day, according to a prearranged titration table. Participants will continue to take their stabilized dose of regular prescribed opioids, both baseline and rescue. Participants will be encouraged to maintain the 20mg daily total dose of Dronabinol. Participants may also reduce their dose of Dronabinol at any time (if they experience severe adverse effects) to a minimum daily dose of Dronabinol of 10mg per day. Participants who cannot tolerate at least a minimum daily dose of 10mg of Dronabinol per day will be discontinued from the study.

Weeks five through twelve is the Opioid-Sparing Period, during which time participants will be encouraged to maintain the stabilized dose of Dronabinol that they "found" during the Study-Drug Dose Finding Period. Study Participants will continue to take their regular prescribed opioids, but will be encouraged to reduce their opioid dose and/or opioid dose frequency at any time during the remainder of the study should they experience a reduction in pain and/or an improvement in opioid-related side effects.

• Study Type: Interventional
• Enrollment (Anticipated): 280
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Kendric B Speagle, BA; Phone Number: 4803559000; Email: kendric@daisyrx.com

Study Locations

• United States
  • Arizona
    • Scottsdale, Arizona, United States, 85255
      • Recruiting
      • Daisy Research, Inc.
      • Contact: KENDRIC B SPEAGLE, BA; Phone Number: 480-355-9000; Email: kendric@daisyrx.com
      • Principal Investigator: Kendric B Speagle, BA

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Ability to read, speak, and understand English;
2. Provision of signed and dated informed consent form;
3. Stated willingness to comply with all study procedures and availability for the duration of the study;
4. Male, Female, or Transgender aged > 18;
5. In fair and stable general health as evidenced by medical history and physical examination, and confirmed by prescriber;
6. Participants who have been diagnosed with a pain condition that has not adequately responded to other treatments, in the judgement of the provider;
7. Participants who are currently taking a stabilized dose of opioid analgesics, and who have been taking opioid analgesics for at least 3-months, and who report a score of > 3 on the Brief Pain Inventory 0-10 severity index.;
8. Ability to take medications as prescribed and willingness to adhere to the study-drug regimen;
9. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to enrollment and agreement to use such a method during study participation;
10. Agreement to abstain from the use of cannabis or other cannabinoid compounds, other than the study-drug Dronabinol, throughout study duration;

Exclusion Criteria:

1. Current substance abuse by self-report;
2. Current use of cannabis or other cannabinoid compounds;
3. Significant baseline nausea, vomiting, sedation, or other symptoms reported by physician and or patient that may compromise the collection of study-related data;
4. A history of seizures, head trauma, and or mental illness ;
5. Pregnancy or lactation;
6. Known allergic reactions to components of Dronabinol;
7. Taking any of the following drugs:

Strong CYP2C9 Inhibitor (e.g., amiodarone, fluconazole) Strong CYP3A4 Inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, erythromycin) Potent CYP2C9 or CYP3A4 inducers (e.g., rifampicin) Drugs that are highly protein-bound (e.g., warfarin, cyclosporine, amphotericin B)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Baseline Opioid; One of Seven existing Baseline Opioid subgroups (Hydrocodone, Oxycodone, Morphine, Hydromorphone, Buprenorphine, Tramadol) coadministered with intervention drug, Dronabinol.	Drug: Dronabinol; Dronabinol coadministered with patient's existing Baseline Opioid.; Other Names: Marinol

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pain Intensity Scale (0-10)	To measure the change in pain intensity from baseline using the Opioid Sparing Diary Toolkit. The measurement of the pain intensity will be derived from the Brief Pain Inventory (Short-Form) item #3. "Please rate your pain by marking the box beside the number that best describes your pain at its worst in the last 24 hours." The score is reported as a value between 0 and 10, with 0 indicative of no pain, and 10 indicative of "pain as bad as you can imagine". The score will be considered a continuous level of measurement.	Daily (Days 1-82)
Self-Reported Opioid Use (Opioid Dose)	To measure the change in opioid dose from baseline using the Opioid Sparing Diary Toolkit	Daily (Days 1-82)
Self-Reported Opioid Use Frequency (Opioid Dose Frequency)	To measure the change in opioid use frequency from baseline using the Opioid Sparing Diary Toolkit	Daily (Days 1-82)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Brief Pain Inventory (BPI)	To evaluate and measure any changes in pain history, intensity, location, relief, and life interference indicators from baseline	Study Visits 1-5 (Days 1, 14, 28, 56, 82)
Hospital and Anxiety Depression Scale (HADS)	To measure the change in depression and generalized anxiety from baseline. The HADS measures levels of anxiety and depression that a patient is experiencing. The HADS is a fourteen item scale. Seven of the items relate to a factor that measures anxiety and seven relate to a factor that measures depression. The seven items for each factor are summed into a total score and range from 0 to 21, with higher scores indicative of greater anxiety/depression. The scores will be analyzed as continuous level variables and one-sided paired-samples t-tests will be used to compare mean scores for anxiety and depression for all subjects between Week 1 (baseline) and Week 12 (EOS).	Study Visits 1-5 (Days 1, 14, 28, 56, 82)
Side Effect Checklist 29-item	To evaluate the presence or absence of side effects associated with the intervention	Study Visits 1-5 (Days 1, 14, 28, 56, 82)
RAND Health Survey 36-item	To measure the change in overall quality of life from baseline	Study Visits 1-5 (Days 1, 14, 28, 56, 82)
MOS Sleep Scale	To measure the change in quality of sleep from baseline. The MOS Sleep Scale Self Report includes 12 items which measure 7 individual continuous-level factors relating to sleep quality: (a) sleep disturbances, (b) snoring, (c) sleep short of breath or headache, (d) sleep adequacy, (e) sleep somnolence, (f) sleep problems index I, and (g) sleep problems index II. Each of the seven factors is scored via a two-step process such that higher resulting scores are indicative of greater sleep problems. All 7 scores are measured at the continuous level.	Study Visits 1-5 (Days 1, 14, 28, 56, 82)
Treatment Satisfaction Questionnaire for Medication (TSQM)	To measure the change in satisfaction with medication from baseline	Study Visits 1-5 (Days 1, 14, 28, 56, 82)
Bowel Function Inventory-Revised (BFI-R)	To measure the change in Opioid-Induced Constipation from baseline	Study Visits 1-5 (Days 1, 14, 28, 56, 82)
Current Opioid Misuse Measure (COMM)	To measure the change in Possible Opioid Misuse from baseline	Study Visits 1-5 (Days 1, 14, 28, 56, 82)
Numerical Opioid Side Effect (NOSE) Assessment	To measure the change in Opioid Side Effect Severity from baseline	Study Visits 1-5 (Days 1, 14, 28, 56, 82)
OSD: Mood Scale Self Report (0-10)	To measure the change in Mood from baseline. The Mood Scale is a 10 item Likert-scaled instrument with each of the 10 items scored from 1 = absolutely miserable to 10 = absolutely happy. The scores for each of the 10 items will be summed into a mood total score. The mood total score can range from 10 to 100, with higher scores indicative of happier states. The mood total score is a continuous level of measurement.	Daily (Days 1-82)
OSD: Sleep Scale Self Report (0-10)	To measure the change in Quality of Sleep from baseline. The Sleep Scale is a 10 item Likert-scaled instrument with each of the 10 items scored from 1 = worst imaginable to 10 = best . The scores for each of the 10 items will be summed into a sleep total score. The sleep total score can range from 10 to 100, with higher scores indicative of better quality sleep. The sleep total score is a continuous level of measurement.	Daily (Days 1-82)
OSD: Bowel Movement 24-Hour Self Report Survey	To measure the change in number of Bowel Movements from baseline	Daily (Days 1-82)
FITBIT: Sleep Tracker	To measure the change in quantity and quality of sleep from baseline	Daily (Days 1-82)
FITBIT: Distance Tracker	To measure the change in average weekly distance traveled from baseline	Daily (Days 1-82)
FITBIT: Caloric Expenditure Tracker	To measure the change in average weekly calories expended from baseline	Daily (Days 1-82)
Medical Billing Claims Data for each participant	To evaluate the change in Health Care Expenditures Related To Chronic Pain from baseline (average monthly expenditures before study)	Study Visits 1 & 5 (Days 1 & 82)

Collaborators and Investigators

• Sponsor: Daisy Pharma Opioid Venture, LLC
• Investigators: Principal Investigator: Kendric B Speagle, BA, Daisy Research

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2018
• Primary Completion (Anticipated): June 1, 2019
• Study Completion (Anticipated): July 1, 2019

Study Registration Dates

• First Submitted: November 30, 2018
• First Submitted That Met QC Criteria: December 4, 2018
• First Posted (Actual): December 6, 2018

Study Record Updates

• Last Update Posted (Actual): December 6, 2018
• Last Update Submitted That Met QC Criteria: December 4, 2018
• Last Verified: December 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pain; Neurologic Manifestations; Chronic Pain; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Analgesics, Non-Narcotic; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Psychotropic Drugs; Hallucinogens; Cannabinoid Receptor Agonists; Cannabinoid Receptor Modulators; Dronabinol
• Other Study ID Numbers: 140635

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: Undecided

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No